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Abstract Short-lasting unilateral neuralgiform headache
with conjunctival injection and tearing (SUNCT) is one of
the rarest and most serious headache disorders. Cases of
symptomatic SUNCT syndromes are reported, which
demonstrate that brain imaging is very important for
diagnosis. In this study, we describe the ﬁrst case of sec-
ondary SUNCT syndrome caused by a meningioma. So far,
a clearly effective therapy for SUNCT syndrome has not
been known. In this case, however, SUNCT was com-
pletely responsive to gabapentin. This underlines that this
drug is worthy of being considered as a potential thera-
peutic option in the treatment of SUNCT syndrome.
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Abbreviations
SUNCT Short-lasting unilateral neuralgiform headache
with conjunctival injection and tearing
SUNA Short-lasting unilateral neuralgiform headache
attacks with cranial autonomic features
MRI Magnetic resonance imaging
Introduction
Short-lasting unilateral neuralgiform headache with con-
junctival injection and tearing (SUNCT) is an extremely
rare form of headache. It is characterized by short attacks
of unilateral neuralgiform severe pain accompanied by
autonomic symptoms such as tearing, rhinorrhea and con-
junctival injection [1–3]. SUNCT is a subset of SUNA
(short-lasting unilateral neuralgiform headache attacks
with cranial autonomic features) that shows similar head-
ache attacks, but different cranial autonomic symptoms [4].
SUNCT syndrome is, as well as cluster headache and
paroxysmal hemicranias, classiﬁed as a trigeminal auto-
nomic cephalalgia (TAC). A possible pathophysiological
mechanism of these headache disorders is a hypothalamic
activation as shown by functional MRI studies [3, 5].
However, several symptomatic SUNCT syndromes
caused by intracerebral tumors and non-tumorous lesions
are reported. For instance, prolactinomas [6] and vascular
malformations [7] have been described. So far, meningio-
mas have not been reported.
A deﬁnitely effective drug therapy is not known. Pla-
cebo-controlled studies do not exist. However, there are
some case reports that demonstrate the potential efﬁcacy of
lamotrigine, gabapentin, topiramate and intravenous lido-
caine [2, 3, 8].
We report a case of secondary SUNCT syndrome caused
by a meningioma fully responsive to gabapentin.
Case report
An 81-year-old woman presented with a 5-month history of
headache.Shehadnotpresentedearlierbecausesheintended
to commit suicide due to severe facial pain. The patient
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with a stabbing and neuralgiform quality, which spread out
from the left forehead to the left temple and cheek. The very
short-lasting attacks occurred about 60 times daily with a
common occurrence at night. Triggers could not be found
out. The attacks were accompanied by lacrimation, con-
junctival injection, nasal congestion and rhinorrhea.
Physical examination showed a slight protrusion of the
left eyeball, hypesthesia of the left side of the face and a
left hearing impairment.
Brain MRI (magnetic resonance imaging) demonstrated
an inﬁltrative growing left extraaxial fronto-temporal mass
of about 2 9 3.4 9 3.5 cm that was T2 hyperintense and
T1 isointense. It showed furthermore a clear contrast
medium enhancement with a meningeal tail sign that was
pathognomonic for meningiomas (see Fig. 1).
Because of her comorbidity consisting of cardiovascular
diseases, the patient denied surgery. Therefore, we decided
to start a symptomatic therapy. With a daily dosage of
1,800 mg gabapentin, the patient was completely free of
complaints.
One month later, the patient presented again with severe
headache. In the meantime, the pain medication was
changed from gabapentin to an opioid due to serial rib
fracture. As the opioid was not effective in the treatment of
the patient’s headache, gabapentin therapy was reestab-
lished. The patient was again asymptomatic with a daily
dosage of 1,800 mg gabapentin.
Discussion
The patient fulﬁlls the criteria of the International Head-
ache Society for SUNCT syndrome [1, 2]. The side and
symptoms of this SUNCT syndrome are in accordance with
the location of the meningioma. That is why we assume a
causal relation. However, this causality could not be con-
ﬁrmed in the end because the patient refused an operation
due to her comorbidity. To our knowledge, this is the ﬁrst
case reporting a SUNCT syndrome probably caused by a
meningioma. Since a lot of other symptomatic SUNCT
syndromes are described [6, 7], this case underlines
that brain MRI is essential for the diagnosis of SUNCT
syndrome.
Because of the favorable side effect proﬁle, we settled
for a symptomatic therapy with gabapentin. In contrast to
pregabalin, its dosage can be increased more rapidly.
Gabapentin has an inhibitory effect on voltage-gated cal-
cium channels and is used as an antiepileptic drug as well
as in the treatment of neuropathic pain. In this case, it was
shown that the patient’s neuralgiform pain was completely
reactive to gabapentin, but not to opioids.
This case demonstrates that it is worth giving gabapentin
a trial in the treatment of SUNCT syndrome.
Conﬂict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Sjaastad O, Saunte C, Salvesen R, Fredriksen TA, Seim A, Roe
OD, Fostad K, Lobben OP, Zhao JM (1989) Shortlasting unilateral
neuralgiform headache attacks with conjunctival injection, tearing,
sweating, and rhinorrhea. Cephalalgia 9:147–156
Fig. 1 Magnetic resonance
imaging of the fronto-temporal
meningioma. a MRI shows the
left-sided fronto-temporal
inﬁltrative growing
T2-hyperintense tumor
(asterisk) and (b, c)a
T1-contrast medium
enhancement (arrow). Note the
meningeal tail sign, which is
pathognomonic for
meningiomas (arrow)
360 J Headache Pain (2010) 11:359–361
1232. May A, Leone M, Afra J, Linde M, Sandor PS, Evers S, Goadsby
PJ, EFNS Task Force (2006) EFNS guidelines on the treatment of
cluster headache and other trigeminal autonomic cephalalgias. Eur
J Neurol 13:1066–1077
3. Cohen AS (2007) Short-lasting unilateral neuralgiform headache
attacks with conjunctival injection and tearing. Cephalalgia
27:824–832
4. Cohen AS, Matharu MS, Goadsby PF (2006) Short-lasting
unilateral neuralgiform headache attacks with conjunctival injec-
tion and tearing (SUNCT) or cranial autonomic features
(SUNA)—a prospective clinical study of SUNCT and SUNA.
Brain 129:2746–2760
5. Matharu M, May A (2008) Functional and structural neuroimaging
in trigeminal autonomic cephalalgias. Curr Pain Headache Rep
12:132–137
6. Massiou H, Launay JM, Levy C, El Amrani M, Emperauger B,
Bousser MG (2002) SUNCT syndrome in two patients with prolac-
tinomasandbromocriptine-inducedattacks.Neurology58:1698–1699
7. Mondejar B, Cano EF, Perez I, Navarro S, Garrido JA, Velasquez
JM, Alvarez A (2006) Secondary SUNCT syndrome to a variant of
the vertebrobasilar vascular development. Cephalalgia 26:620–622
8. Etemadifar M, Maghi AH, Ghasemi M, Chitsaz A, Kaji Esfahani
M (2008) Efﬁcacy of gabapentin in the treatment of SUNCT
syndrome. Cephalalgia 28:1339–1342
J Headache Pain (2010) 11:359–361 361
123